NASDAQ: AKTSAktis Oncology Inc Stock Ownership - Who owns Aktis Oncology?
Insider buying vs selling
Have Aktis Oncology Inc insiders been buying or selling?
Buy
Sell
| Name | Role | Date | Shares | Price | Value |
|---|---|---|---|---|---|
| Ecor1 Capital LLC | Director | 2026-01-12 | 2,077,779 | $18.00 | $37.40MBuy |
| Ecor1 Capital LLC | Director | 2026-01-12 | 144,443 | $18.00 | $2.60MBuy |
| Todd Foley | Director | 2026-01-12 | 232,870 | $18.00 | $4.19MBuy |
| Ansbert Gadicke | 10% Owner | 2026-01-12 | 1,112,777 | $18.00 | $20.03MBuy |
| Helen Susan Kim | Director | 2026-01-12 | 812,455 | $18.00 | $14.62MBuy |
| Helen Susan Kim | Director | 2026-01-12 | 22,545 | $18.00 | $405.81kBuy |
| Mpm Bioventures 2018 LP | 10% Owner | 2026-01-12 | 1,112,777 | $18.00 | $20.03MBuy |
| Vida Ventures II LLC | 10% Owner | 2026-01-12 | 812,455 | $18.00 | $14.62MBuy |
| Vida Ventures II LLC | 10% Owner | 2026-01-12 | 22,545 | $18.00 | $405.81kBuy |
AKTS insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership
Be the first to know when AKTS insiders and whales buy or sell their stock.
AKTS Shareholders
What type of owners hold Aktis Oncology Inc stock?
Institutional
Insider
Retail
| Name | Hold | Shares | Value | Type |
|---|---|---|---|---|
| Mpm Bioventures 2018 LP | 19.21% | 10,260,064 | $181.30M | Insider |
| Ansbert Gadicke | 19.21% | 10,260,064 | $181.30M | Insider |
| Lilly Co Eli | 11.88% | 6,344,114 | $112.10M | Insider |
| Todd Foley | 7.93% | 4,235,403 | $74.84M | Insider |
| Ecor1 Capital LLC | 0.65% | 347,305 | $6.14M | Insider |
| Helen Susan Kim | 0.29% | 157,387 | $2.78M | Insider |
| Vida Ventures II LLC | 0.29% | 157,387 | $2.78M | Insider |
| Paul L. Feldman | 0.27% | 144,568 | $2.55M | Insider |
| Matthew Roden | 0.17% | 91,998 | $1.63M | Insider |
| Lloyd Mitchell Segal | 0.04% | 19,631 | $346.88k | Insider |
AKTS vs Biotech Stocks
Aktis Oncology Stock Ownership FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.